Non-small-cell lung cancer (NSCLC) is one of the most dynamic oncology indications and a key area of focus for drug developers. Immune checkpoint inhibitors have transformed the management of advanced NSCLC. In late 2018, Tecentriq (Roche / Genentech / Chugai) was the second immune checkpoint inhibitor to enter the coveted first-line metastatic setting, after Keytruda (Merck & Co.). Competition is set to intensify as multiple combination therapies based on immune checkpoint inhibition gain approval and enter the clinic. In addition, novel biomarker-driven therapies such as next-generation EGFR and ALK inhibitors are vying for a share of this increasingly crowded and competitive market.

Questions Answered

  • How large are the drug-treatable NSCLC populations, and how will drug-treatment rates change over time in market-relevant populations?
  • How will recent and expected market approvals shape the uptake of immune checkpoint inhibitors for the first-line treatment of metastatic NSCLC? Which agents and combinations will dominate this commercially lucrative disease setting?
  • What pipeline products are most promising, and what uptake and sales could they secure in NSCLC? What therapies of note are progressing in earlier phases of development?
  • What are the key market drivers and constraints in NSCLC, and how will the market evolve over the forecast period?

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.


Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: 16 country-specific interviews with experts and 210 country-specific surveys with medical oncologists treating NSCLC.

Epidemiology: Diagnosed and recurrent incidence of adenocarcinoma, squamous cell carcinoma, large cell carcinoma and other, and unverified NSCLC.

Population segments in market forecast: Stage IB/II, stage III, first line, second line, and third line for metastatic adenocarcinoma, squamous cell carcinoma, large cell carcinoma and other, and unverified NSCLC.

Emerging therapies: Phase I/II: 13 drugs; Phase III / PR: 17 drugs.

Table of contents

  • Disease Landscape & Forecast
    • COVID-19
    • Key Findings
    • Key Updates
      • May 2020
      • December 2019
      • September 2019
      • May 2019
    • Market Outlook
      • Key Findings
      • COVID-19: Areas of Potential Forecast Impact
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for NSCLC?
        • What Factors Are Constraining the Market for NSCLC?
      • Segment-Specific Trends
        • Stage IB-II NSCLC
        • Stage III NSCLC
        • First-Line Treatment of Metastatic NSCLC
        • Second- and Third-Line Treatment of Metastatic NSCLC
    • Forecast
      • Market Forecast Assumptions
      • Market Forecast Dashboard
    • Etiology and Pathophysiology
      • Disease Overview
        • Disease Overview
      • Disease Pathophysiology
        • Progression of NSCLC
      • Staging and Classification
        • Classification of NSCLC
        • Staging of NSCLC
      • Key Pathways and Drug Targets
    • Epidemiology
      • Key Findings
      • Epidemiology Populations
        • Diagnosed Incident Cases
        • Stage Distribution at Diagnosis
        • Recurrent Incident Cases
        • Drug-Treatable Populations
        • Drug-Treated Populations
    • Current Treatment
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • EGFR Inhibitors
        • ALK Inhibitors
        • ROS1 Inhibitors
        • BRAF/MEK Inhibitors
        • Immune Checkpoint Inhibitors
        • Angiogenesis Inhibitors
        • Cytotoxic Agents
      • Medical Practice
        • Region-Specific Treatment Practices
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in NSCLC
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • EGFR Inhibitors
        • ALK Inhibitors
        • MET Inhibitors
        • RET Inhibitors
        • KRAS inhibitors
        • Immune Checkpoint Inhibitors
        • Bispecific Antibodies
        • Angiogenesis Inhibitors
        • Poly ADP-Ribose Polymerase Inhibitors
        • Therapeutic Vaccines
        • Cytokine-Targeted Therapies
        • Cytotoxic Agents
      • Early-Phase Pipeline Analysis
    • Access and Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
      • Looking for More?
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug- and Regimen-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • General Statements About Pricing
        • Dosing, Cycles of Therapy, and Compliance
        • Generic Erosion
        • Biosimilar Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • NSCLC Bibliography

Author(s): Ann-Marie Looney, M.Sc., Ph.D; Atul Sharma, MPH

Ann-Marie Looney, is a Business Insights Analyst in the oncology team at Decision Resources Group. Prior to joining DRG, Dr Looney worked as a postdoctoral researcher for the National Children’s Research Centre and the Irish Centre for Fetal and Neonatal Translational Research, Ireland where her work centred on the discovery and validation of biomarkers of early childhood injury and disease, with a specific focus on early childhood obesity, neonatal brain injury and autism spectrum ; She has a in Neuroscience, a by research in molecular biology and a in clinical and translational research from University College Cork, Ireland.

Atul Sharma started working in Decision Resources Group as an intern in early 2016 and currently works as an associate epidemiologist. He performs fully documented systematic reviews of both published and grey literature on the epidemiology of assigned diseases and their risk factors to estimate incidence/prevalence over a 10-30 year period. He produces analyses for pharmaceutical drug developers on the descriptive epidemiology of major drug indications in mature and developing markets. He holds a Master’s in Public Health degree from School of Public Health, Post-Graduate Institute of Medical Education and Research and a Bachelor’s in dental surgery from MN DAV Dental College & Hospital.

Related Reports

Non-Small-Cell Lung Cancer | Access & Reimbursement | Detailed, Expanded Analysis (US)

The high number of premium-priced non-small-cell lung cancer (NSCLC) therapies and the large number of NSC...

View Details

Non-Small-Cell Lung Cancer | Geographic Focus: China | Non-Small-Cell Lung Cancer | China In-Depth | China

Non-small-cell lung cancer (NSCLC)—the leading cause of cancer-related deaths in China—has a highly dynamic drug development pipeline, with multiple targeted and biomarker-driven ther...

View Details

Non-Small-Cell Lung Cancer | Unmet Need | Detailed, Expanded Analysis: EGFR-positive metastatic non-squamous NSCLC (US & EU)

EGFR-mutation-status determination is a mandatory step in the treatment algorithm for patients with advanced non-small-cell lung can...

View Details

Non-Small-Cell Lung Cancer | Disease Landscape and Forecast | G7 | 2019

Non-small-cell lung cancer (NSCLC) is one of the most dynamic oncology indications and a key area of focus for drug developers. Immune checkpoint inh...

View Details